The proportion of older people in the total population has increased in Turkey as well as worldwide. As life expectancy rises, the increasing prevalence of rheumatic diseases poses major problems in the elderly. Comorbid diseases and the aging-induced changes in the endogenous immune response and the pharmacokinetic properties of therapeutic agents may complicate the decision to use a particular drug and result in a different clinical picture and treatment response. We, therefore, aimed to investigate the characteristics of chronic inflammatory diseases, their impact on physical function and quality of life, the prevalence of comorbid diseases that may complicate treatment planning, and treatment adherence in patients aged 65 years or older. One hundred seventy-four patients were included and divided into two age groups: 18–64 years (group 1, n = 85) and 65 years or older (group 2, n = 89). The mean age of all recruited patients was 57.55 ± 16.98 years. Of 174, 99 (56.9%) were female and 75 (43.1%) were male. The mean duration of rheumatic disease was 7 ± 4.8 years and age at onset was 51.46 ± 14.78 years. Gender distribution differed significantly by age group (P = 0.024). The percentage of females in group 1 was 48.2% and 65.2% in group 2. The occupational status also differed significantly by age group (P < 0.001). 48.2% of group 1 were employed and 57.3% of group 2 were housewives. Marital status varied significantly by age (P < 0.001). The percentage of married was 74.1% in group 1 and the percentage of separated/divorced/widowed in group 2 was 28.1%. There was no difference between groups 1 and 2 in terms of place of residence (P = 0.459). The prevalence of comorbid diseases and the rate of use of medications for comorbid diseases (non-rheumatic treatments) were higher in elderly patients. The rate of use of disease-modifying anti-rheumatic drugs (DMARDs) was 30.3% and biological agents 61.8% in the elderly group (≥ 65 years) (group 2) (P < 0.001). There were positive correlations between, Health Assessment Questionnaire (HAQ), Bath Ankylosing Spondylitis Functional Index (BASFI) and Nottingham Health Profile (NHP) domains in both groups. There was also a significant negative correlation between Medication Adherence Rating Scale (MARS) and all dimensions. Elderly and younger patients with rheumatic diseases have different demographic and clinical characteristics. Physical function and quality of life are more affected by rheumatic diseases and treatment adherence is poorer in the elderly. Our study found a positive correlation between physical function and quality of life in both age groups. The treatment adherence rating scale showed a negative correlation with physical function and quality of life scores, with individuals with poor treatment adherence having worse physical function and quality of life.
S100A8 and S100A9 play a crucial role in immune system functions. S100 proteins are expressed in different cell types and have important roles in regulating various cellular processes and in the haemostasis of the immune system. The aim of this study was to investigate the association between serum S100A8/S100A9 levels and disease-related variables in patients with psoriatic arthritis (PsA), healthy controls, and individuals with psoriasis. 62 PsA patients, 52 healthy controls and 54 psoriasis patients were included. Sociodemographic and clinical characteristic of the groups were recorded. Serum levels of S100A8 and S100A9 were accessed in all groups by ELISA. In the psoriasis group, the S100A8 level was statistically lower and the S100A9 level was statistically higher than in the PsA and control groups. In the PsA group, there was a statistically significant positive correlation between S100A9 level and number of tender and swollen joints and DAPSA score. In the PsA group, there was a statistically significant negative correlation between S100A8 level and number of tender joints, VAS, DAPSA and BASDAI scores. In the PsA group, there was no significant correlation between S100A8-S100A9, CRP and ESR, MSHS and PASRI radiological scores. In psoriasis patients, we found positive correlation between BMI and S100A9 levels. S100A9 level, the number of swollen and tender joints in the PsA group correlated with DAPSA. S100A9 can be used as a new molecule in the follow-up of PsA disease activity, and it may be associated with psoriasis. The lower stability of S100A8 compared to S100A9 and its susceptibility to oxidation suggest that it may not be suitable for diagnosis of PsA. The results were showed that there are limitations regarding the use of these biomarkers in routine diagnosis and follow-up.